We are deeply grateful to our stellar Board of Directors for their advice, advocacy, counsel and support. Our Board includes a dynamic group of individuals who play a critical role in developing the LAM Health Project’s strategic plan and ensuring that we are able to meet the ambitious goals we set for ourselves.
Gail S. Ebner is a consultant and provides advisory and executive support services in clinical operations to biopharmaceutical companies. Ms. Ebner has pharmaceutical research experience spanning Phase I-IV international clinical studies in multiple therapeutic areas. Her successful project management has culminated in approved NDA products by the FDA. Ms. Ebner has proven success managing interdisciplinary teams and building effective coalitions with internal and external business partners. Having worked for both pharmaceutical companies and CROs, Ms. Ebner is skilled at contract negotiations and CRO management. Ms. Ebner has over 30 years of responsible decision-making, strong leadership, and loyal team building. Ms. Ebner was recognized for her volunteer work by the San Diego Performing Arts League in 2010 and was awarded a Star Award. Ms. Ebner has served on the Board of Trustees for the La Jolla Playhouse and is currently a Member of the Board of Directors for ion Theatre in San Diego.
Ronald C. Dorazio, MD
In 1992, Dr. Dorazio co-founded Genetix Pharmaceuticals, now Bluebirdbio, a gene therapy company specializing in the safe and efficient viral delivery of therapeutic genes. Prior to this, Dr. Dorazio was Founder and Vice President of Lifecodes Corporation, the first commercial laboratory to adapt molecular biology to forensic and paternity testing.
Dr. Dorazio has a B.S. from the University of Notre Dame and an M.D. from New York Medical College. He is Board-Certified in Internal Medicine and completed a Hematology/Oncology Fellowship at the Memorial Sloan-Kettering Cancer Center.
Dr. Niemi is Director, Animal Welfare Assurance, Massachusetts General Hospital and Instructor in Pathology, Harvard Medical School. With over 35 years experience in biomedical research and commercial biotechnology, he has held senior management positions in contract drug and device development, biotech start-ups in gene therapy and genomics, and laboratory animal care. Dr. Niemi earned an AB in Biology from Harvard College, a DVM from Washington State University, and then received a US Public Health Service National Research Service Award while a Postdoctoral Fellow at the Massachusetts Institute of Technology. He later completed the Program for Management Development at the Harvard Business School.
Mr. Shedd has over 35 years experience within the technology, biopharmaceutical and government sectors. Mr. Shedd began his career with Coopers&Lybrand (now PriceWaterhouseCoopers) and for over 20 years has been the Chief Financial Officer of publically traded, privately held and government entities, such as TSI Corporation, a publically traded contract research organization that performed pre-clinical and clinical trials for major pharmaceutical and bio-technology companies and Clearblue Technologies, a privately held managed services provider, providing co-location services in the technology sector. Since 2003, Mr. Shedd has been the Chief Financial Officer of the United States Government Printing Office (USGPO), where he is the main point of contact for financial matters between the United States Congress and the USGPO.
Mr. Shedd has a B.A. in Economics from Brandeis University and an M.B.A. from Boston University.